Cocrystal Pharma Q2 10-Q: Going Concern Persists Despite $5M OPKO Placement
COCP sits 42% above its 52-week low of $0.76.
Summary
Cocrystal Pharma's Q2 10-Q reiterates a going concern warning, with cash of $2.244 million and a $5 million OPKO placement that still leaves a funding gap for the next 12 months.
Key Events · Earnings and Guidance · COCP
-
Going Concern Warning Reiterated
The 10-Q states that the company's cash of $2.244 million as of June 30, 2026, plus the $5 million raised from OPKO Health on July 31, 2026, will not be sufficient to fund operations for 12 months following the filing.
-
OPKO Placement Quantified
The filing discloses that the July 31, 2026 private placement with OPKO Health involved 5,474,053 shares at $0.9134 per share, resulting in gross proceeds of $5.0 million.
-
Cash Burn Continues
Net loss for the six months ended June 30, 2026 was $5.463 million, with net cash used in operating activities of $4.856 million.
-
Research and Development Spending Rises
R&D expenses increased to $3.513 million for the first half of 2026, up from $2.482 million in the prior year, driven by the CDI-988 norovirus Phase 1b trial.
Analysis · COCP · Life Sciences
Cocrystal Pharma's Q2 10-Q confirms the company's going concern warning remains in effect. Cash and restricted cash totaled $2.244 million as of June 30, 2026, and management states that even with the $5 million raised from OPKO Health on July 31, 2026, funds will not cover 12 months of operations. The filing quantifies the OPKO placement: 5,474,053 shares at $0.9134 per share. The company continues to burn cash, with a net loss of $5.463 million for the first half of 2026. This is a critical liquidity update for a micro-cap biotech.
At the time of this filing, COCP was trading at $1.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.4M. The 52-week trading range was $0.76 to $2.67. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.